Airfinity launches new platform IDA 360 to track all infectious disease vaccine and treatment candidates

Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape.

Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive intelligence, providing clear and near real-time updates on candidate development, clinical trials, approvals, regulatory changes and more. 

Airfinity IDA covers

• ~2,000 candidates across ~150 infectious diseases
• ~2,000 clinical trials across 113 countries
• ~300 approvals captured and ~100 candidate expedited status